Skip to main content
. 2022 Feb 25;19:13. doi: 10.1186/s12981-022-00435-6

Table 1.

Feasible restrictions placed on attributes and levels for each mode of treatment

Attribute Levels Restrictions by mode of administration
LA Oral SC injection IM injection Implant All modes
Mode LA Oral, SC Injection, IM Injection, Implant*
Frequency 1, 4, 8, 12, 26, 52 weeks 1 or 4 weeks 1, 4, 8, or 12 weeks 4, 8, or 12 weeks 26 or 52 weeks IF location = clinic or pharmacy, THEN dose frequency ≥ 4
Location Home, pharmacy, clinic Only home Any Not home Only clinic IF frequency = 1 week, THEN location = home
Pain None, mild, moderate Only none None or mild Mild or moderate Mild or moderate
Oral lead-in 0, 3, 6 months
Negative reaction testing Yes or no
Late dose leeway Short, long*

*Long-acting oral tablet, subcutaneous injection, intramuscular injection

*Short vs Long: For the late dose leeway attribute, the duration of time displayed to respondents for both the "short" and "long" levels was dependent on the dosing frequency of that alternative